JP2014503178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503178A5 JP2014503178A5 JP2013532287A JP2013532287A JP2014503178A5 JP 2014503178 A5 JP2014503178 A5 JP 2014503178A5 JP 2013532287 A JP2013532287 A JP 2013532287A JP 2013532287 A JP2013532287 A JP 2013532287A JP 2014503178 A5 JP2014503178 A5 JP 2014503178A5
- Authority
- JP
- Japan
- Prior art keywords
- tau
- antibody
- seq
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000013498 tau Proteins Human genes 0.000 claims description 83
- 108010026424 tau Proteins Proteins 0.000 claims description 83
- 239000012634 fragment Substances 0.000 claims description 46
- 230000027455 binding Effects 0.000 claims description 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 31
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 20
- 208000034799 Tauopathies Diseases 0.000 claims description 19
- 206010012289 Dementia Diseases 0.000 claims description 18
- 230000000626 neurodegenerative effect Effects 0.000 claims description 17
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 8
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 7
- 206010034010 Parkinsonism Diseases 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010059245 Angiopathy Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 206010018341 Gliosis Diseases 0.000 claims description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 102000029749 Microtubule Human genes 0.000 claims description 4
- 108091022875 Microtubule Proteins 0.000 claims description 4
- 208000026072 Motor neurone disease Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 4
- 102000029797 Prion Human genes 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 4
- 230000002308 calcification Effects 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 230000007387 gliosis Effects 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 201000008319 inclusion body myositis Diseases 0.000 claims description 4
- 210000004688 microtubule Anatomy 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 210000002241 neurite Anatomy 0.000 claims description 4
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 230000002739 subcortical effect Effects 0.000 claims description 4
- 208000033556 type C1 Niemann-Pick disease Diseases 0.000 claims description 4
- 208000004434 Calcinosis Diseases 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
- 208000024571 Pick disease Diseases 0.000 claims description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 239000000523 sample Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims description 2
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 210000004227 basal ganglia Anatomy 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000001054 cortical effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 102000057063 human MAPT Human genes 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 238000012634 optical imaging Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000002600 positron emission tomography Methods 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000003325 tomography Methods 0.000 claims description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 208000013044 corticobasal degeneration disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39175110P | 2010-10-11 | 2010-10-11 | |
| US61/391,751 | 2010-10-11 | ||
| EP10013494.9 | 2010-10-11 | ||
| EP10013494 | 2010-10-11 | ||
| PCT/IB2011/002786 WO2012049570A1 (en) | 2010-10-11 | 2011-10-11 | Human anti-tau antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016016975A Division JP6300842B2 (ja) | 2010-10-11 | 2016-02-01 | ヒト抗タウ抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014503178A JP2014503178A (ja) | 2014-02-13 |
| JP2014503178A5 true JP2014503178A5 (enExample) | 2014-10-16 |
Family
ID=43602869
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532287A Pending JP2014503178A (ja) | 2010-10-11 | 2011-10-11 | ヒト抗タウ抗体 |
| JP2016016975A Expired - Fee Related JP6300842B2 (ja) | 2010-10-11 | 2016-02-01 | ヒト抗タウ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016016975A Expired - Fee Related JP6300842B2 (ja) | 2010-10-11 | 2016-02-01 | ヒト抗タウ抗体 |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US8940272B2 (enExample) |
| EP (1) | EP2627672B1 (enExample) |
| JP (2) | JP2014503178A (enExample) |
| CN (1) | CN103339146B (enExample) |
| AU (1) | AU2011315181B2 (enExample) |
| BR (1) | BR112013008765B8 (enExample) |
| CA (1) | CA2813493C (enExample) |
| CY (1) | CY1120951T1 (enExample) |
| DK (1) | DK2627672T3 (enExample) |
| EA (1) | EA031698B1 (enExample) |
| ES (1) | ES2686550T3 (enExample) |
| HR (1) | HRP20181320T8 (enExample) |
| IL (1) | IL225670B (enExample) |
| LT (1) | LT2627672T (enExample) |
| MX (1) | MX345092B (enExample) |
| NZ (1) | NZ609984A (enExample) |
| PL (1) | PL2627672T3 (enExample) |
| PT (1) | PT2627672T (enExample) |
| SG (1) | SG189174A1 (enExample) |
| SI (1) | SI2627672T1 (enExample) |
| TR (1) | TR201812636T4 (enExample) |
| WO (1) | WO2012049570A1 (enExample) |
| ZA (1) | ZA201303175B (enExample) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| US8940272B2 (en) | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| DK2794654T3 (da) * | 2011-12-20 | 2019-08-05 | Janssen Biotech Inc | Anti-phf-tau-antistoffer og deres anvendelser |
| SG10201913370PA (en) * | 2012-07-03 | 2020-03-30 | Univ Washington | Antibodies to tau |
| WO2014016737A1 (en) * | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
| SI2885010T1 (sl) | 2012-08-16 | 2020-07-31 | Ipierian, Inc. | Metode zdravljenja tauopatije |
| US20140056901A1 (en) * | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| BR112015014751A8 (pt) * | 2012-12-21 | 2018-01-16 | Biogen Int Neuroscience Gmbh | anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos. |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| CA2902026C (en) * | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| US9598485B2 (en) * | 2013-03-15 | 2017-03-21 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
| EA039554B1 (ru) * | 2013-06-10 | 2022-02-09 | АйПИЕРИАН, ИНК. | Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости |
| GB201312226D0 (en) * | 2013-07-08 | 2013-08-21 | Adx Neurosciences | Improved antibodies |
| WO2015081085A2 (en) * | 2013-11-27 | 2015-06-04 | Ipierian, Inc. | Methods of treating a tauopathy |
| AU2014368696A1 (en) | 2013-12-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Humanized anti-Tau(pS422) antibodies and methods of use |
| CN105939722A (zh) | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau肽，抗Tau抗体，及其使用方法 |
| BR112016029579A2 (pt) * | 2014-06-26 | 2017-08-22 | Janssen Vaccines & Prevention Bv | anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos |
| ZA201608812B (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| EA201790165A1 (ru) | 2014-07-29 | 2017-07-31 | Нейриммьюн Холдинг Аг | Происходящие от человека антитела к гентингтину (htt) и их применение |
| KR102502356B1 (ko) * | 2014-09-30 | 2023-02-21 | 워싱턴 유니버시티 | 타우 (tau) 활동 계측 |
| EP3204411A4 (en) * | 2014-10-10 | 2018-03-28 | National Research Council of Canada | Anti-tau antibody and uses thereof |
| ES2848376T3 (es) * | 2014-11-19 | 2021-08-09 | Axon Neuroscience Se | Anticuerpos de tau humanizados en la enfermedad de Alzheimer |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| EP3261670A4 (en) | 2015-02-24 | 2018-08-01 | Rpeptide, LLC | Anti-tau antibodies |
| JO3576B1 (ar) | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
| WO2016164530A1 (en) * | 2015-04-07 | 2016-10-13 | University Of Maryland, College Park | Compositions and methods for high throughput protein sequencing |
| UA126272C2 (uk) | 2015-06-05 | 2022-09-14 | Дженентек, Інк. | Антитіло проти тау-білка та спосіб його застосування |
| CN113929779B (zh) | 2015-06-24 | 2025-02-25 | 豪夫迈·罗氏有限公司 | 人源化的抗-Tau(pS422)抗体和使用方法 |
| MA41670A1 (fr) * | 2015-07-06 | 2018-05-31 | Ucb Biopharma Sprl | Anticorps se liant a tau |
| TN2017000543A1 (en) | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| CN105388302A (zh) * | 2015-12-22 | 2016-03-09 | 中国医学科学院输血研究所 | 一种人免疫球蛋白制品中Tau蛋白抗体含量的检测方法 |
| EP4063858A1 (en) | 2016-03-14 | 2022-09-28 | Biogen International Neuroscience GmbH | Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins |
| DK3452507T3 (da) | 2016-05-02 | 2022-11-14 | Prothena Biosciences Ltd | Tau-immunoterapi |
| SG11201808434WA (en) | 2016-05-02 | 2018-10-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| CU24538B1 (es) | 2016-05-02 | 2021-08-06 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7 |
| MX2018015022A (es) | 2016-06-07 | 2019-08-14 | Biogen Int Neuroscience Gmbh | Métodos para el tratamiento de la enfermedad de alzheimer. |
| NZ748983A (en) | 2016-07-12 | 2022-12-23 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| EP3487524A4 (en) * | 2016-07-20 | 2020-03-25 | Anahit Ghochikyan | HUMANIZED ANTI-TAU ANTIBODIES, COMPOSITIONS AND MANUFACTURING METHODS AND METHODS OF USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES |
| US20190330318A1 (en) | 2016-07-25 | 2019-10-31 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
| CA3032692A1 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination antibody therapy for the treatment of neurodegenerative diseases |
| US11072639B2 (en) | 2016-09-08 | 2021-07-27 | Regenerative Research Foundation | Bi-functional anti-tau polypeptides and use thereof |
| US10889635B2 (en) | 2016-11-15 | 2021-01-12 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| MX2019006334A (es) | 2016-12-07 | 2019-08-01 | Genentech Inc | Anticuerpos antitau y métodos de uso. |
| US20200031895A1 (en) | 2016-12-16 | 2020-01-30 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| JP2020508054A (ja) * | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| US11028157B2 (en) * | 2017-03-28 | 2021-06-08 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| EP3601337A1 (en) | 2017-03-28 | 2020-02-05 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
| JP2020515846A (ja) * | 2017-03-28 | 2020-05-28 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | タウタンパク質凝集を調節する化合物の検出のための方法 |
| BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
| JP2020529394A (ja) * | 2017-06-16 | 2020-10-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | タウオパチーを治療するための組成物及び方法 |
| EP4233901A3 (en) | 2017-08-22 | 2023-09-06 | Biogen MA Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| EA202090604A1 (ru) | 2017-10-02 | 2020-10-15 | Мерк Шарп энд Доум Корп. | Хроманмонобактамовые соединения для лечения бактериальных инфекций |
| UA129617C2 (uk) | 2017-10-16 | 2025-06-18 | Еісаі Р Енд Д Менеджмент Ко., Лтд. | Антитіло до тау та його застосування |
| CN111447951A (zh) * | 2017-12-04 | 2020-07-24 | 扬森疫苗与预防公司 | 与tau特异性结合的结合分子 |
| EP3724232B1 (en) | 2017-12-14 | 2024-12-04 | The University of Ottawa | Exosome packaging and targeted autophagy |
| US12398201B2 (en) | 2018-02-19 | 2025-08-26 | New York University | Tau single domain antibodies |
| NL2020520B1 (en) * | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
| AU2019232631A1 (en) * | 2018-03-05 | 2020-09-24 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
| WO2019175735A1 (en) * | 2018-03-11 | 2019-09-19 | Koorosh Shahpasand | Conformation-independent antibodies against neurotoxic tau proteins |
| EP3829634A1 (en) | 2018-07-31 | 2021-06-09 | Eli Lilly and Company | Combination therapy |
| KR20210111242A (ko) | 2018-10-29 | 2021-09-10 | 바이오젠 엠에이 인코포레이티드 | 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체 |
| SG11202104549TA (en) * | 2018-11-08 | 2021-05-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| CA3131531A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CA3135170A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| US20220218805A1 (en) * | 2019-05-27 | 2022-07-14 | The University Of British Columbia | Conformation-specific epitopes in tau, antibodies thereto and methods related thereof |
| GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| JP7181438B2 (ja) | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
| CN114502781B (zh) | 2019-09-20 | 2025-06-17 | 纳维再生科技股份有限公司 | 个人化癌症免疫治疗 |
| US20230265175A1 (en) | 2020-06-25 | 2023-08-24 | Merck Sharp & Dohme Llc | High affinity antibodies targeting tau phosphorylated at serine 413 |
| EP4271708A1 (en) * | 2020-12-29 | 2023-11-08 | Neurimmune AG | Human anti-tau antibodies |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| MX2024002295A (es) | 2021-08-27 | 2024-03-07 | Genentech Inc | Metodos para tratar las patologias de tau. |
| WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
| WO2024026472A2 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| KR20240162497A (ko) | 2022-03-14 | 2024-11-15 | 제넨테크, 인크. | 음성 분석에 기반한 신경퇴행성 질환 예측 |
| EP4544544A1 (en) | 2022-06-21 | 2025-04-30 | Genentech Inc. | Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses |
| WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2024133723A1 (en) | 2022-12-22 | 2024-06-27 | Institut National de la Santé et de la Recherche Médicale | Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy |
| CN116948025B (zh) * | 2023-09-14 | 2024-04-02 | 北京凯祥弘康生物科技有限公司 | 一种抗Tau蛋白的抗体 |
| CN117106081B (zh) * | 2023-09-28 | 2024-05-07 | 北京凯祥弘康生物科技有限公司 | 一种抗nfl蛋白的捕获抗体 |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| CN117969825A (zh) * | 2024-02-18 | 2024-05-03 | 上海信利健康管理有限公司 | 一种人尿液中的磷酸化Tau蛋白的胶体金免疫层析检测卡及其制备方法 |
| WO2025185739A1 (en) * | 2024-03-08 | 2025-09-12 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric tau |
| WO2025264572A1 (en) | 2024-06-17 | 2025-12-26 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| CN119661705B (zh) * | 2024-11-22 | 2025-06-24 | 上海伯杰医疗科技股份有限公司 | 一种抗p-Tau217蛋白单克隆抗体及其制备方法和应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| JPH02503867A (ja) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Ｉｌ‐２レセプター特異的キメラ抗体 |
| EP0428534B1 (en) | 1988-06-14 | 1995-03-29 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| ES2178635T3 (es) | 1990-11-09 | 2003-01-01 | Stephen D Gillies | Inmunoconjugados de citoquinas. |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| WO1993008302A1 (en) * | 1991-10-25 | 1993-04-29 | Itt Automotive Europe Gmbh | Monoclonal antibodies directed against the microtubule-associated protein tau |
| EP0746609A4 (en) * | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス，インク． | 異種抗体の生産 |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DE669986T1 (de) | 1992-11-13 | 1996-10-10 | Idec Pharma Corp | Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung. |
| JP2879975B2 (ja) | 1992-12-14 | 1999-04-05 | エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム | 微小管関連タンパク質タウに対するモノクローナル抗体、これらの抗体を分泌するハイブリドーマ、これらのモノクローナル抗体による抗原認識及びこれらの応用 |
| AU698383B2 (en) | 1993-12-21 | 1998-10-29 | Innogenetics N.V. | Monoclonal antibodies specific for PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications |
| ATE234324T1 (de) | 1994-07-29 | 2003-03-15 | Innogenetics Nv | Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| PL191251B1 (pl) | 1997-03-14 | 2006-04-28 | Idec Pharma Corp | Sposób wprowadzania żądanego DNA w docelowe miejsce w genomie ssaka i układ wektorów |
| DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| AU1631700A (en) | 1998-11-23 | 2000-06-13 | Idec Pharmaceuticals Corporation | Tumor antigen-specific antibody-gp39 chimeric protein constructs |
| US20040110938A1 (en) | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| JP4368196B2 (ja) | 2000-11-17 | 2009-11-18 | ユニバーシティー オブ ロチェスター | 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法 |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| EP1373321A2 (en) | 2001-01-29 | 2004-01-02 | Idec Pharmaceuticals Corporation | Modified antibodies and methods of use |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| AU2002355477B2 (en) * | 2001-08-03 | 2008-09-25 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
| DE60219925T2 (de) | 2001-08-24 | 2008-01-17 | Universität Zürich | Methode zur induzierung neurofibrillärer tangles in transgenen tieren |
| US20030157641A1 (en) | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
| WO2004016655A1 (ja) | 2002-08-14 | 2004-02-26 | Mitsubishi Chemical Corporation | 中枢性タウ蛋白質特異的抗体 |
| US20060240485A1 (en) | 2003-04-24 | 2006-10-26 | Universitat Zurich | Method of monitoring immunotherapy |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| JP4730584B2 (ja) * | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| US7083854B1 (en) | 2005-05-10 | 2006-08-01 | Cornell Research Foundation, Inc. | Fibers from polymer nanoclay nanocomposites by electrospinning |
| US20080300204A1 (en) | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
| WO2007068105A1 (en) * | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| EP2099826B1 (en) | 2007-01-05 | 2013-10-16 | University Of Zurich | Anti-beta-amyloid antibody and uses thereof |
| AU2009299073B2 (en) * | 2008-09-16 | 2015-04-02 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2010144711A2 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| WO2011053565A2 (en) | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
| EP2625198B1 (en) | 2010-10-07 | 2015-07-22 | AC Immune S.A. | Antibodies recognising phospho-tau |
| US8940272B2 (en) | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| WO2012149365A2 (en) | 2011-04-27 | 2012-11-01 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
| US20120323214A1 (en) | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
| BR112015014751A8 (pt) | 2012-12-21 | 2018-01-16 | Biogen Int Neuroscience Gmbh | anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos. |
-
2011
- 2011-10-11 US US13/271,118 patent/US8940272B2/en active Active
- 2011-10-11 MX MX2013003879A patent/MX345092B/es active IP Right Grant
- 2011-10-11 EA EA201390453A patent/EA031698B1/ru unknown
- 2011-10-11 SI SI201131553T patent/SI2627672T1/sl unknown
- 2011-10-11 SG SG2013023775A patent/SG189174A1/en unknown
- 2011-10-11 CN CN201180048980.7A patent/CN103339146B/zh not_active Expired - Fee Related
- 2011-10-11 BR BR112013008765A patent/BR112013008765B8/pt not_active IP Right Cessation
- 2011-10-11 NZ NZ609984A patent/NZ609984A/en not_active IP Right Cessation
- 2011-10-11 PT PT11797115T patent/PT2627672T/pt unknown
- 2011-10-11 ES ES11797115.0T patent/ES2686550T3/es active Active
- 2011-10-11 DK DK11797115.0T patent/DK2627672T3/en active
- 2011-10-11 TR TR2018/12636T patent/TR201812636T4/tr unknown
- 2011-10-11 WO PCT/IB2011/002786 patent/WO2012049570A1/en not_active Ceased
- 2011-10-11 JP JP2013532287A patent/JP2014503178A/ja active Pending
- 2011-10-11 CA CA2813493A patent/CA2813493C/en active Active
- 2011-10-11 HR HRP20181320TT patent/HRP20181320T8/hr unknown
- 2011-10-11 EP EP11797115.0A patent/EP2627672B1/en active Active
- 2011-10-11 LT LTEP11797115.0T patent/LT2627672T/lt unknown
- 2011-10-11 PL PL11797115T patent/PL2627672T3/pl unknown
- 2011-10-11 US US13/878,839 patent/US20130295021A1/en not_active Abandoned
- 2011-10-11 AU AU2011315181A patent/AU2011315181B2/en not_active Ceased
-
2013
- 2013-04-10 IL IL225670A patent/IL225670B/en active IP Right Grant
- 2013-04-30 ZA ZA2013/03175A patent/ZA201303175B/en unknown
-
2014
- 2014-11-04 US US14/532,531 patent/US9605059B2/en not_active Expired - Fee Related
-
2016
- 2016-02-01 JP JP2016016975A patent/JP6300842B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-08 US US15/427,733 patent/US20180002409A1/en not_active Abandoned
-
2018
- 2018-09-12 US US16/128,978 patent/US20190233506A1/en not_active Abandoned
- 2018-11-01 CY CY181101135T patent/CY1120951T1/el unknown
-
2020
- 2020-09-17 US US17/023,814 patent/US20210238265A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503178A5 (enExample) | ||
| JP2015505665A5 (enExample) | ||
| JP2017205118A5 (enExample) | ||
| IL225568A (en) | Phospho-specific antibodies for tau detection | |
| JP2012512634A5 (enExample) | ||
| DK2732289T3 (en) | ANTIBODIES, KIT AND IN VITRO METHOD FOR DETECTING BETA AMYLOID OLIGOMERS | |
| JP7676556B2 (ja) | 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用 | |
| JP2018534236A5 (enExample) | ||
| JP2017522886A5 (enExample) | ||
| US11022618B2 (en) | Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43 | |
| JP2014528695A5 (enExample) | ||
| JP2018535921A5 (enExample) | ||
| JP2017532288A5 (enExample) | ||
| HRP20150831T1 (hr) | Humana anti-alfa- sinuklein auto-protutijela | |
| JP2014502141A5 (enExample) | ||
| CN104662423A (zh) | 阿兹海默氏病的诊断、预后和监测中的寡聚体Aβ | |
| JP2018516849A5 (enExample) | ||
| FI3334761T3 (fi) | Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa | |
| CN116348769A (zh) | 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定 | |
| US20200278358A1 (en) | Method of distinguishing between different neurodegenerative diseases | |
| Gao et al. | Peptoid nanosheet-based sensing system for the diagnosis and surveillance of amnestic mild cognitive impairment and Alzheimer’s disease | |
| JP7197494B2 (ja) | 抗Ｔａｕナノボディ | |
| US20220260593A1 (en) | Targets and methods of diagnosing, monitoring and treating frontotemporal dementia | |
| US10570195B2 (en) | Conformation-independent antibodies against neurotoxic tau proteins | |
| WO2017184973A1 (en) | Identifying amyloidogenic proteins & amyloidogenic risk |